why choose us

First received: November 14, 2022

Clinical Trial: Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neovascular Age-related Macular Degeneration

Study Type: INTERVENTIONAL


Official Title: A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI333 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Brief Summary: This study is designed for multi-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single and multiple intravitreal injection of IBI333 in subjects with neovascular age-related macular degeneration (nAMD).

Read more